In this theoretic note, the rationale for the physical decay correction of the 18 F-FDG input function in dynamic PET is investigated, using the Patlak equation as an example. Methods: The Patlak equation conventionally obtained when correcting the 18 F-FDG input function and correcting the tissue activity measurement for 18 F physical decay can also be derived from a 2-compartment analysis that does not conceptually involve any physical decay correction of the 18 F-FDG input function but accounts only for the physical decay of the trapped tracer. Results: We demonstrate that exactly the same equation can be derived from the 2 conceptual approaches, and hence each approach yields the correct uptake rate of the tracer. Conclusion: No advantage in 18 F-FDG dynamic PET can be expected from using the concept of uncorrected data rather than that of decay-corrected data. Nevertheless, conceptually, we show that correcting the 18 F-FDG input function for radioactive decay cannot be justified and that this correction is not compatible with the calculation of patient radiation dose.
Wi th 18 F FDG PET, physicians can measure 18 F-FDG uptake and hence obtain insight into the glucose metabolism rate. The increase in the tracer uptake of rapidly proliferating tumors can be assessed either by a semiquantitative analysis, that is, the standardized uptake value (1) , or by quantitative kinetic analyses. Different methods of quantitative kinetic analyses have been described (2-7). These methods always require an estimate of the input function, that is, of the blood time-activity curve of the tracer, to determine the quantity of tracer that is made available to the tissues at each time point (8) . This input function can be obtained by arterial sampling.
Data obtained from blood sampling, that is, the 18 F-FDG blood time-activity curve, as well as data from PET, that is, the 18 F-FDG tissue time-activity curve, are conventionally corrected for the 18 F physical decay (4, (9) (10) (11) (12) . However, after the 18 F radioactive decay, (i.e., 18 F is transformed into 18 O), any blood-borne 18 F-FDG molecule has been definitely changed into a different molecule and is then no longer available for the tissue. The relevance of the 18 F-FDG input function decay correction is thus questionable, and this note aims at showing that it is not conceptually justified. Here, as an example, we take a 2-compartment model in which it is assumed that no decay correction of the input function is needed, but which accounts for the physical decay of the trapped tracer, and compare it with the conventional Patlak analysis as often used in kinetic analysis of 18 F-FDG PET data (2, 3) , that is, using in particular a decay-corrected input function.
MATERIALS AND METHODS

Two-Compartment Model Without Input Function Decay Correction
A 2-compartment model has been previously developed to measure 18 F-FDG uptake in tissues, assuming that the tracer is trapped irreversibly (13, 14) . In this model, the rate of trapped tracer change per tissue volume at steady state, dC T /dt, is described by: dC T =dt 5 KC p ðtÞ 2 l C T ðtÞ;
Eq. 1 where C p (t) is the tracer plasma concentration at time t, K is the uptake rate constant (assuming an irreversible uptake), and the second term accounts for the 18 F decay of the tracer trapped in the tissues. C p (t) is not corrected for radioactive decay as it is assumed that, after 18 F decay, an 18 F-FDG molecule has been changed into a different molecule and will no longer be metabolized as 18 F-FDG. The solution of Equation 1 is (13, 14) :
The total quantity of radioactive molecules, at time t, per tissue volume unit, C Tot (t), without any additional decay correction can be derived from Equation 2 by including the free tracer in the blood and interstitial volumes:
The parameters f b and f i are the fractions of blood and interstitial fluid volumes in the tissue volume, respectively. Equation 3 can be rewritten as (13) 
where C Tot * (t) is defined as the total quantity of tracer at time t per tissue volume unit that includes both trapped tracer and free tracer in the blood and interstitial volumes. The K parameter is the tracer uptake rate constant as defined in Equation 1. C p * (t) is defined as the tracer plasma concentration at time t. The parameters f b and f i are the fractions of blood and interstitial fluid volumes, respectively, in the tissue volume as defined in Equation 3. The original paper by Sokoloff et al. (15) did not involve any physical decay correction, because 14 C-deoxyglucose was used, and the 14 C period (about 5,700 y) was much greater than the experiment's duration. When 18 F-FDG is considered, C Tot * (t) and C p * (t) are conventionally corrected for physical decay thus: Eq. 10
RESULTS
The 2 conceptual approaches are compared in Figure 1 , with the 2 compartments involving free 18 F-FDG in the blood (compartment A) and 18 F-FDG trapped in intracellular cytoplasm (compartment B). The time-activity curves of the molecules are shown in each compartment, without or with 18 F decay correction. The uncorrected 18 F-FDG blood timeactivity curve within compartment A has been drawn assuming, for simplicity, a monoexponential (physical 1 biologic) decay, with a rate constant a 5 0.0188 min 21 , according to literature data (9, 12) . Then, the trapped 18 F-FDG timeactivity curve within compartment B has been derived from Equation 2, yielding (13, 14) :
2lt 2 e 2at Þ=ða 2 lÞ: Eq. 11
The decay-corrected 18 F-FDG blood time-activity curve within compartment A has been derived from Equation 7 , that is, assuming only a biologic decay, and the decaycorrected time-activity curve of trapped 18 Assuming irreversible trapping and according to Equations 4 and 10, the same 18 F-FDG uptake rate constant occurs between the 2 compartments whether a decay correction occurs or not. In Figure 1 , the value of K has been arbitrarily set to 0.05 min 21 , according to literature data (16) . Therefore, the Patlak plot, without or with decay-corrected data, that is, from Equation 11 or from Equation 12, and from uncorrected or decay-corrected input functions, respectively, provides exactly the same graph with a linear slope of 0.05 min 21 (graph not shown).
DISCUSSION
A 2-compartment model in which it is assumed that no decay correction of the input function is needed has been compared with Patlak analysis that conventionally uses a FIGURE 1. Theoretic free 18 F-FDG blood time-activity curve and trapped 18 F-FDG tissue time-activity curve included in compartments A and B, respectively, when no 18 F decay correction is applied (solid line) and when 18 F decay correction is applied (dashed line). a.u. 5 arbitrary unit.
decay-corrected 18 F-FDG input function (Fig. 1) . The use of decay-corrected data is not specific to Patlak analysis, but this example has allowed us a comparison with an analytic solution provided by the 2-compartment model. Equation 4 provided by the 2-compartment model analysis and Equation 10 provided by the Patlak analysis are identical, and hence each approach yields the correct uptake rate of the tracer. Therefore, this note does not present a new method, and simulations investigating different tracers (in particular with fast-decaying radionuclides) cannot discriminate between the 2 conceptual approaches. In other words, no advantage in 18 F-FDG quantitative imaging can be obtained using the concept of uncorrected data (17) rather than that of decay-corrected data. Nevertheless, this note emphasizes that correcting the 18 F-FDG input function for radioactive decay cannot be conceptually justified and that this correction is not compatible with the calculation of patient radiation dose.
Derivation of Equation 4 accounts only for the physical decay of trapped tracer in the tissues. On the other hand, Equation 10 was obtained after explicit decay correction of both the input function and the tissue activity value. The right-hand sides of Equations 4 and 10 are identical, but the exponential function exp(lt) associated with the input function comes from 2 different origins as a function of the derivation involved: It comes from the physical decay of the trapped tracer in Equation 4 and from a physical decay correction of the input function in Equation 10 . Once 18 F has emitted a positron, it becomes 18 O, and hence a blood-borne 18 F-FDG molecule is likely to be transformed into a blood glucose molecule. Correcting an 18 F-FDG input function for the physical decay of the tracer does not appear conceptually justified because, after 18 F decay, a blood-borne 18 F-FDG molecule has definitely changed into a different molecule. Therefore, the original blood-borne 18 F-FDG molecule is no longer available for the tissue, and the transformed molecule does not significantly compete with the remaining blood-borne 18 F-FDG (compared with its competition with blood glucose molecules) since the experiment is performed at tracer dose. In fact, the competition of the blood-transformed molecule with blood-borne 18 F-FDG would not exist if the transformed molecule were not a glucose molecule, for example, if the radioactive tracer were 11 C-deoxyglucose. Therefore, it does not appear legitimate to correct the 18 F-FDG input function for radioactive decay. Yet, conventional Patlak analysis uses an input function decay correction. This correction goes along with a decay correction of the tissue tracer activity yielding a correct formula and hence the correct uptake rate of the tracer and explains why the conventional approach is effective. However, our derivation suggests that the justification of an exponential function exp(lt) associated with the input function in the correct formula may be explained from a 2-compartment model and should not be considered an input function decay correction as in a conventional Patlak derivation.
Furthermore, this line of argument also highlights that correcting the 18 F-FDG input function for radioactive decay is not compatible with the calculation of patient radiation dose. Indeed, 18 F physical decay occurring with blood 18 F-FDG molecules must be considered for calculations of the blood radiation dose (Fig. 1) . The 2-compartment model, in which it is assumed that no decay correction of the input function is needed, agrees with kinetic models for absorbed dose calculation (18) .
CONCLUSION
Although no advantage in 18 F-FDG dynamic PET can be expected by using the concept of uncorrected data rather than that of decay-corrected data, this note nevertheless shows that correcting the 18 F-FDG input function for radioactive decay cannot be conceptually justified and that this correction is not compatible with the calculation of patient radiation dose.
